The influence of dietary and supplemental omega-3 fatty acids on the omega-3 index: A scoping review

Introduction: The majority of the population do not consume adequate omega-3 fatty acids (n-3 FA), leading to global deficiencies, as evidenced by poor omega-3 status. An indicator of overall n-3 FA status, omega3-index (O3i) ≥8% has been associated with reduced risk of chronic disease, most notably cardiovascular disease. Thus, a synthesis of current research summarizing the effects of n-3 FA intake on O3i is warranted to develop and refine clinical recommendations. The purpose of this scoping review was to evaluate the effect of n-3 FA interventions and estimate sufficient n-3 FA intake to improve O3i to meet recommendations.

Methods: Search criteria were human studies published in English from 2004 to 2022 that assessed O3i at baseline and following an n-3 FA intervention.

Results: Fifty-eight studies that met inclusion criteria were identified. Protocols included fish consumption, fortified foods, combined eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplements, supplements of single n-3 FA (alpha linolenic acid (ALA), EPA, DHA, etc.), and supplements providing multiple n-3 FA. Dietary supplements varied in chemical composition; the most common were triglycerides or ethyl esters. The lowest supplementation protocol was 100 mg/d, and the largest was 4,400 mg/d EPA and DHA. Supplementation time period ranged from 3 weeks to 1 year. At baseline, three study samples had mean O3i >8%, although many intervention protocols successfully increased O3i.

Discussion: Generally, the lowest doses shown to be effective in raising O3i to recommended levels were >1,000 mg/d of combination DHA plus EPA for 12 weeks or longer. Supplements composed of triglycerides were more bioavailable and thus more effective than other formulas. Based on the data evaluated, practical recommendations to improve O3i to ≥8% are consumption of 1,000–1,500 mg/d EPA plus DHA as triglycerides for at least 12 weeks.

Introduction

Poor intake of omega-3 fatty acids (n-3 FA) is worldwide, stimulating a scientific and commercial interest in this essential lipid. High consumption of n-3 FA's has been associated with improved cardiovascular health, decreased anxiety and depression, as well as reduced rates of cancer, Alzheimer's Disease, type 1 Diabetes, multiple sclerosis, and total mortality (1). The primary dietary n-3 FA's are alpha linolenic acid (ALA; C18:3n-3), eicosapentaenoic acid (EPA; C20:5n-3), and docosahexaenoic acid (DHA; C22:6n-3). Only ALA has a dietary reference intake (DRI) of 1.1–1.6 g/d, although experts have advised recommendations for EPA and DHA (2, 3), since elongation of ALA produces limited longer chain n-3 FA (4). Sources of ALA include plant oils (e.g., flaxseed, and soybean) as well as some algae. EPA and DHA are found in fatty fish such as salmon, tuna, herring, and mackerel. Due to inadequate synthesis of EPA and DHA from ALA, many professional organizations have established recommendations for fish consumption. The 2015 Dietary Guidelines for Americans (DGA) and the American Heart Association recommend consuming two servings of fish per week (3.5–4-oz. per servings), to reach an intake of 250 mg/d of EPA and DHA. However, the majority of the American population consumes approximately half of the recommended 7–8 oz. fish per week (5). NHANES data have estimated mean fish intake among adults is 4 oz. per week and only 1 oz. per week if limiting to fish high in n-3 FA. This fish intake translates to dietary n-3 FA short of 250 mg/d, with an estimated mean consumption of 63 ± 2 mg/d DHA (72 ± 4 mg/d including supplements) and 23 ± 1 mg/d EPA (41 ± 4 mg/d including supplements). Therefore, developing evidence-based recommendations and approaches to include more n-3 FA's into the diet is essential for ensuring long term health and wellness.

Research suggests that even those who consume fish regularly have a low omega-3 index (O3i) (1), defined as the ratio of EPA and DHA to total fatty acids in erythrocyte membranes indicative of overall n-3 FA status. O3i has been shown to reflect tissue n-FA distribution and is more representative of long-term n-3 FA dietary intake than other assessment methods (6). Furthermore, O3i is commonly measured in clinical and research settings via quick and non-invasive blood spot analysis. However, calculation of O3i may vary by laboratory. In 2004, Harris and Schacky (7) initiated O3i research after showing that individuals with O3i >8% had lower risk of cardiovascular disease vs. those with <4%. Further evidence has supported health benefits of maintaining O3i >8% (1), which is a lofty target considering a high percentage of individuals assessed have O3i in the highest risk category <4% (8–16). Current recommendations for ALA intake and fish consumption are inadequate for most individuals to maintain a healthy O3i. According to a cross-sectional study, 83% of those consuming at least two servings of fatty fish per week had an O3i <8%, and only those consuming fish regularly plus supplementing with >1,000 mg/d EPA and DHA maintained optimal O3i (1). Globally, n-3 FA intake and blood concentrations fall well below recommendations, showing worldwide deficiency and elevated risk for chronic disease (15). Therefore, the purpose of this scoping review was to evaluate the effect of n-3 FA interventions and explore sufficient n-3 FA intake to meet O3i recommendations. While increasing dietary n-3 FA's generally improves the O3i, the response depends on type of n-3 FA, dose, chemical composition, duration, and participant characteristics (such as sex, age, genotype menopausal status among other factors that determine lipid distribution). We synthesized available literature to create practical recommendations to reach optimal O3i status in the general population.

Methods

Research databases (Pubmed, Medline, and Google Scholar) were searched for peer-reviewed articles evaluating changes in the O3i following a dietary or supplemental intervention (Figure 1). Search dates were 2004–2022 based on the pivotal publication by Harris and Schacky that established the O3i as an indicator of cardiovascular disease risk, sparking an influx of research (7). Search terms were “omega-3 fatty acids, omega-3 fatty acid supplement, omega-3 index, ALA, EPA, DHA.” Inclusion criteria were publication in English, human participants, defined n-3 FA intervention, and assessment of O3i at baseline as well as follow-up. Studies were excluded for including previously published intervention data or using retrospective data. To be evaluated, studies were required to specify n-3 FA acid intervention by dose and time period as well as present baseline and follow-up O3i. Types of interventions include dietary supplements, fortified foods, oils, and fish containing EPA, DHA, ALA, or a combination of mixed n-3 FA. There were no limitations based on participant age, health status, pregnancy, or other conditions.

FIGURE 1

Figure 1. PRIMSA flow chart showing study selection for scoping review.

Results

Search results

We identified 58 original research articles that evaluated the effect of n-3 FA on O3i (Tables 1–4; Figures 2–4). Many studies used multiple interventions to compare formulas, doses, and type of n-3 FA; thus, the total number of individual cohorts presented exceeds 58 articles. These intervention protocols included dietary consumption of fish (n = 1), fortified foods (n = 9), oils (n = 6), supplements of single n-3 FA (n = 16), and supplements providing a combination n-3 FA (n = 52). Dietary supplements varied in chemical composition; the most common were triglycerides (TAG) or ethyl esters (EE). The lowest intervention dose was supplemental 100 mg/d EPA plus DHA (8), and the largest was 4,400 mg/d EPA plus DHA (17, 18). Time period of intervention ranged from 3 weeks (19) to 1 year (16, 20).

TABLE 1

Table 1. Combination EPA plus DHA supplementation protocols and omega-3 index (O3i).

FIGURE 2

Figure 2. Change in omega-3 index (O3i) from baseline for protocols using combined EPA + DHA separated by dose. Data are presented as means ± SD (if available in publication). Legend shows length of supplementation/fortification in parentheses. (A) Doses less than 500 mg/d; (B) Doses ranging from 500–1,000 mg/d; (C) Doses ranging from 1,000–1,500 mg/d; (D) Doses ranging from 1,500–2,000 mg/d; (E) Doses ranging from 2,000–3,000 mg/d; (F) Doses exceeding 3,000 mg/d.

Study participants resided in a variety of countries and continents, including North America, Europe, Asia, and Australia. Characteristics of individuals varied widely, showing strong representation of age ranges, male and female, and healthy as well as those with chronic disease. In this analysis, sex, age, and chronic disease appeared to have no effect on the response to n-3 FA supplementation compared to healthy individuals. The lowest mean baseline O3i was 1.1 ± 1.2% in Italian children with hyperlipidemia (21), and the highest was 9.4 ± 3.7% in healthy German adults (22). Fatty acid extraction and calculation of O3i differed between these laboratories, thus making direct comparison of O3i concentrations challenging.

Three studies (5 sample cohorts) reported mean baseline O3i ≥8%, which were measured in Austrian and German laboratories (22–24). About half of the studies reviewed found that participants' O3i increased to ≥8% following the intervention period, although nearly all supplementation protocol significantly improved O3i from baseline. The smallest dose to reach >8% O3i was 200 mg/day of DHA for nearly 6 months in pregnant women (25) (Table 3, 1.5% increase from baseline). The largest dose, used in two studies, was 4,400 mg/day combination of DHA and EPA for 1–3 months (17, 18) (Table 1, 4–7% increase from baseline). The largest overall improvement in O3i was 9% increase from baseline following 6 weeks of fortified margarine containing 2,300 mg/d DHA (22) (Table 3). While fish consumption and other food fortification protocols significantly increased O3i from baseline, the magnitude of change was smaller compared to supplemental n-3 FA. Consumption of oils had little impact on O3i, showing mixed statistical changes with minimal clinical significance (Table 4). In general, participants' O3i levels increased by a greater magnitude as supplementation dose increased (Figures 2–4).

DHA and EPA

Fifty-eight intervention protocols (from 43 publications) used a combination of EPA and DHA (Table 1). Participants consumed supplemental dosages ranging from 100 (8) to 4,400 mg/d (17, 18) over study periods from as little as 3 weeks (19) to as long as 1 year (16, 20). Food fortification protocols provided considerably lower EPA and DHA compared to supplements, ranging from an estimated 150 mg/d to 350 mg/d (26–30). Dietary n-3 FA from fish consumption had poor study compliance with fewer than half of participants willing to consume fish three time per week, thus falling short of target 400 mg/d (31).

All combination EPA/DHA interventions show statistically significant improvement in O3i, with magnitude of change ranging from 0.3 (8) to 7.6% (32) (Figure 2). Twenty of these intervention protocols (34%) improved participant O3i ≥8%, plus three that significantly increased O3i despite baseline levels ≥8% (23, 24). The most conservative dose to raise O3i ≥8% was 840 mg/d EPA and DHA ethyl esters for 6 months in American adults with non-alcoholic fatty liver disease, whose O3i rose from 5 to 8% (33). Four months of a smaller dose (415 mg/d) mixed with fruit and vegetable juice showed similar 3% improvement in Austrian participants whose baseline O3i exceeded 8% (23). While this supplementation period exceeded many protocols, other research has demonstrated that conservative doses were effective over a shorter supplementation period. In a sample of German adults, participants consumed 840 mg/d EPA and DHA for the first 4 weeks, followed by 1,680 mg/d EPA and DHA for the next 4 weeks to raise O3i from 5% to >8% (34). It remains unclear whether the initial dose would have achieved O3i within the recommended range, as levels had increased significantly above baseline before the dose was increased. The study that achieved the largest overall increase in O3i (5–13%) supplemented 3,360 mg/d EPA plus DHA for 6 months, improving baseline levels by nearly 8% in a small sample of older American adults (32).

No protocol supplementing EPA and DHA improved mean baseline O3i from <4% to ≥8%, suggesting that high doses over longer time periods are required to bridge the gap between population's O3i levels and optimal recommendations. In general, supplementation with 1,000–1,500 mg EPA and DHA raised O3i by 2–5% regardless of baseline status (Figure 2C). French adults improved from 4 to 9% by supplementing with 1,025 mg/day EPA and DHA for 1 year, showing evidence of the lowest baseline O3i levels that improved to ≥8% (20). American adults receiving dialysis starting with lower O3i had a similar improvement (2–7%), with 1,020 mg/d EPA and DHA for 3 months (12). The shortest protocol to elicit a large change in O3i supplemented 4,400 mg/d EPA and DHA for 1 month, raising O3i from 5 to 9% in American adults (17). Among the highest doses published, this study shows short-term, high-potency supplementation protocols have a comparable O3i improvement to 1,000 mg/d n-3 FA for 3 months or more. Other 3–4 week interventions had ~1% increase in O3i at lower doses, ranging from 300 mg/d in fortified mushrooms to 2,454 mg/d from supplements (19, 27, 35). Most intervention periods were 3–5 months, with many longer interventions showing plateau in O3i following 3 months of supplementation (33, 36, 37).

EPA

Eight intervention protocols supplemented solely with EPA, half of which induced ~ 3% increase in O3i (Table 2, Figure 3). Supplementation with 2,700 mg/d of EPA in re-esterified triglycerides (rTAG) for 10 weeks in Canadian adults increased baseline O3i from 6 to 9% (38). Supplemental doses >3,000 mg/d EPA resulted in a similar 3% O3i increase in two different samples of Canadian adults over 12 weeks, but baseline levels started <4% (10, 39). Likewise, O3i in German adults increased by 3% following 6 weeks of 2,200 mg/d EPA consumed in fortified margarine, but participants had high starting values and O3i showed a high degree of variation (9.4 ± 3.5 to 12.9 ± 3.4%) (22). Lower doses did not have a clinically significant effect on O3i, as 1,000–1,500 mg/d EPA supplementation for 12–16 weeks raised baseline levels by ~ 1% (40–42).

TABLE 2

Table 2. Eicosapentaenoic acid (EPA) supplementation protocols and omega-3 index (O3i).

FIGURE 3

Figure 3. Change in omega-3 index (O3i) from baseline for protocols using EPA. Data are presented as means ± SD (if available in publication). Legend shows dose and length of supplementation/fortification in parentheses.

DHA

Most supplementation with DHA was linked to 4–5% increase in O3i, regardless of baseline values (Table 3, Figure 4). Of the seven intervention protocols that supplemented with DHA, all participants' final mean O3i exceeded 8%, including two samples with baseline O3i <4% (Table 3, Figure 4). Two groups of Canadian adults consuming >3,000 mg/d DHA for 12 weeks improved O3i from 3.5 to 8.4% (10, 39). Surprisingly, this 5% improvement was exceeded in German adults, whose O3i rose from 9.4 ± 3.7 to 18.5 ± 4.2% with consumption of 2,300 mg/d DHA in a fortified margarine for 6 weeks (22). The most conservative dose to improve O3i >8% supplemented 200 mg/day DHA for ~ 5 months in Italian pregnant women, although their baseline O3i was 6.5 ± 1.4% so the magnitude of increase was smaller than protocols using a larger dose (25). Taken together, the evidence suggests that supplementing with DHA raised O3i to a greater extent than EPA or combination formulas.

TABLE 3

Table 3. Docosahexanoic acid (DHA) supplementation protocols and omega-3 index (O3i).

FIGURE 4

Figure 4. Change in omega-3 index (O3i) from baseline for protocols using DHA. Data are presented as means ± SD (if available in publication). Legend shows dose and length of supplementation/fortification in parentheses.

Other omega-3 forms

No other form of n-3 FA had a clinically significant effect on the O3i (Table 4). While some interventions showed a small statistically significant increase in O3i, no protocol raised O3i more than about 1%, and in some cases O3i decreased from baseline. Sources of n-3 FA were flaxseed, rapeseed, sunflower, and hempseed oils high in ALA or soybean and echium oils high in stearidonic acid (SDA; C18:4n-3). Because ALA and SDA have limited elongation to EPA and DHA, consumption of these shorter chain n-3 FA have little effect on the O3i.

TABLE 4

Table 4. Other omega-3 fatty acid (n-3 FA) supplementation protocols and omega-3 index (O3i).

Discussion

The 58 studies included in this n-3 FA scoping review varied widely in dose, chemical composition, intervention period, and participant characteristics (e.g., age, sex, health status, etc.). However, a common theme that emerged was most participants' baseline O3i ranged from 3 to 5%, well below the recommended 8% for reduced risk of chronic disease. Direct comparison of O3i between studies is challenging due to differences in laboratory assessment. The most successful n-3 FA interventions to clinically and statistically improve O3i supplemented >1,000 mg of combination DHA plus EPA or solely DHA for 12 weeks or longer (Figures 2, 3). Due to limited dietary availability, supplementation and/or fortified foods are necessary for most individuals to reach optimal O3i. Handeland et al. (31) compared n-FA intake from fish vs. supplements, finding that dietary compliance from fish consumption was poor (<40%) and inferior compared to dietary supplements in raising O3i. Fortified foods significantly improved O3i by 1–2% with lower doses than dietary supplements (150–350 mg/d EPA + DHA) (26–30). One exception was the use of fortified margarine, which doubled O3i from 9 to 18% following 6 weeks of 2,300 mg/d DHA in German adults, although these high baseline values and large magnitude of change were not observed in most laboratories (22). Choice of fish consumption, fortified foods, or dietary supplements will depend on baseline O3i, food tolerance, and availability.

Although ALA is the only n-3 FA with a DRI, EPA and DHA are also considered essential for a healthy diet. Furthermore, EPA and DHA improve the O3i to a greater extent than ALA. Since DHA is efficiently incorporated into erythrocyte membranes, DHA improves O3i at lower doses than other n-3 FA. ALA and SDA have limited elongation to EPA and negligible effects on DHA concentrations, which is evident from studies that show minimal effect on O3i. Although EPA elongates to DHA, recent research suggests that DHA rarely retroconverts to EPA, instead slowing turnover of EPA to maintain plasma concentrations (43). On the contrary, DHA undergoes few reactions and is incorporated directly into erythrocyte membranes. As a result, DHA was more effective at raising participants' O3i compared to studies which supplemented equal or greater amounts of EPA.

Metherel et al. (43) completed a secondary review of a study that supplemented 3,256 mg/d DHA for 12 weeks to increase participant O3i by 5% compared to a 3% increase in O3i with an equal dose of EPA (10). Using isotopic carbon tracing to determine the origins of the fatty acids, researchers found EPA supplementation significantly increased concentrations of EPA, DHA, and n-3 docosapentaenoic acid (DPA), a 22-carbon FA synthesized from EPA. DHA supplementation, however, increased concentrations of both DHA and EPA, but lack of carbon tracers in EPA provided evidence of slowed metabolism as opposed to retroconversion. These data suggest that EPA elongates to DHA via n-3 DPA as an intermediate, although DHA has limited if any retroconversion to EPA. While EPA may increase O3i to a lesser magnitude than DHA, EPA significantly improves O3i and has important physiological functions such as the synthesis of inflammatory-modulating eicosanoids.

Differences in conversion rates explains why ALA or other forms of n-FA have negligible effects on O3i, which measures the concentration of EPA and DHA in red blood cell membranes. Metherel et al. (43) found that the carbon tracer of the plasma EPA that remained after 12 weeks of DHA supplementation was nearly identical to that of the plasma ALA, suggesting that EPA was synthesized from the preexisting ALA. Therefore, while EPA may be used for in vivo synthesis of DHA and n-3 DPA, ALA has little effect on DHA levels and thus, O3i. In summary, n-3 FA's that undergo the fewest interconversions, e.g., DHA and EPA, have the greatest impact on O3i because they are directly incorporated into the membrane.

In addition to dose and length of supplementation, formula is an important consideration. Common dietary supplement formulas include TAG, rTAG, and EE. However, many of the publications included in this review did not specify chemical composition, even though these structures are metabolized differently. Neubronner et al. (36) conducted a clinical comparing 670 mg DHA + 1,010 mg EPA/d as rTAG vs. EE for 6 months. Although O3i significantly improved in both treatment groups, final O3i was greater with rTAG supplementation (13.3 ± 2.2 vs. 12.2 ± 2.3%), supporting greater bioavailability with rTAG than EE. Authors suggested that pancreatic lipases were more efficient at hydrolyzing fatty acids bound to TAG and transporting these fatty acids in the body. Other research supports better bioavailability from TAG, as another study showed significantly greater improvement in O3i by supplementing DHA and EPA acyl-glycerol (a re-esterified polyunsaturated fatty acid) vs. EE for 8 weeks (46). Protocols that specified TAG n-3 FA formulas for ≥10 weeks found 3–7% improvement in O3i, raising the final concentrations to >8% (32, 38, 39, 47). Taken together, these data support suggest that supplemental n-3FA in the form of TAGs or rTAGs are digested and absorbed better than EEs, although, consumption of a fatty meal improves absorption of both forms of n-3 FA.

In addition to dose and forms of n-3 FA, individual characteristics influence O3i response to supplementation. Due to estrogen, women have higher activity of desaturases than men, leading to greater elongation of ALA to EPA and DHA (48). However, advanced age appears to enhance response to dietary EPA and DHA in both men and post-menopausal women, perhaps owing to reduced turnover of n-3 FA (49). While these factors are important, they account for a small percentage of variability in response to n-3 FA intake. Flock et al. (50) estimated that body weight, baseline O3i, age, physical activity, and sex together accounted for 10% of response, compared to dose, which alone explained 68%. Incorporating this study along with 13 other intervention trials, Walker et al. (51) estimated that 62% of variance in response was explained by EPA and DHA dose, baseline O3i, and formula of supplement, eliminating age and sex from the final model. Neither of these analyses accounted for genotype, which was found to explain 24% of O3i in a model from data collected in the Framingham Heart Study (49). Across the studies included in this review, analyses that separated sex and age did not find large differences in response to supplementation, although some noted baseline O3i were higher in females (13, 50).

Baseline O3i and whole body kinetics further affect response to dietary n-3 FA intake. Individuals with lower n-3 FA concentrations may better incorporate EPA and DHA into erythrocyte membranes, potentially reaching a saturation point (50). Research suggests that erythrocyte n-3 FA concentrations respond in a dose-dependent manner until reaching equilibrium, typically 4–6 months from the start of intervention (52). Studies included in this review that assessed midpoint O3i values showed mixed results, with one showing a plateau after only 6 weeks (53), and others after 3 months (33, 36, 37). One study, however, found continued O3i increases through 4 months of supplementation (23), while another found small decreases from 6 months to 1 year (16). This research suggests that lower doses are likely necessary to maintain O3i than to increase levels from a low baseline.

Limitations to this review include a lack of standardized procedure for assessment of O3i, contributing to variable baseline concentrations. Full analysis of laboratories procedures is beyond the scope of this review.

Conclusion

The O3i was first validated as a risk factor for cardiovascular disease by Harris and Schacky (7) in 2004 and remains a generally accepted measure for determining omega-3 status. The majority of the world population has O3i levels well below the recommended target of ≥8%. Across the 58 studies reviewed, only three study samples from Germany and Austria began with a mean baseline assessment ≥8% (22–24), and laboratory assessment methods may have accounted for these high baseline values. Most mean baseline O3i ranged from 3 to 6%, suggesting that most individuals would benefit from improved omega-3 status, leaving the question of how best to reach optimal levels.

Few individuals meet recommendations for fish consumption, which appear insufficient to reach optimal O3i status even for those who do consume two servings per week (1). The sole study protocol that provided fish for 3 meals per week found low compliance in Norwegian teenagers, although adults may be more tolerant. Dietary interventions with fortified foods showed promise in low doses, highlighting an area for future research. Most supplementation studies did not detail the diet of their participants, using general descriptions such as “low or no habitual consumption of oily fish” (50) or no description at all. Since diet, n-3 FA dose and chemical composition influence individual outcomes, Walker et al. (51) developed a model to predict O3i response to 16 weeks of supplementation. With a baseline O3i of 2–4%, an individual would need to consume 1,500–2,250 mg/d EPA and DHA as TAG's or 2,250–3,250 mg/d EE's to reach 8%. For individuals with baseline O3i from 4 to 6%, a dose of 1,000–1,500 mg/d as TAG's or 1,500–2,250 mg/day as EE's is recommended.

Practical applications

Few individuals meet the target O3i of 8%, increasing their risk of cardiovascular disease among other chronic ailments. Improving O3i with fish alone is neither realistic nor sustainable, leaving fortified foods and/or third-party tested dietary supplements to close the gap. Generally, the lowest doses shown to be effective in raising O3i to recommended levels were >1,000 mg of combination DHA plus EPA or solely DHA for 12 weeks or longer. Supplements composed of TAG were more bioavailable and thus more effective than other formulas. Based on the data evaluated, practical recommendations to improve O3i to ≥8% are consumption of 1,000–1,500 mg/day EPA plus DHA as TAG for at least 12 weeks to improve levels. Those with baseline O3i <4% will likely need longer time periods of supplementation and/or higher doses. Research evaluated was to improve O3i rather than maintain healthy levels so the appropriate dose for maintenance is an area for future research.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

MD, MR, and LW contributed to design and editing of the manuscript. MD conducted the literature review with assistance by LW and MR. MD and LW drafted the manuscript. MR critically edited the manuscript. All authors read and approved the final submission.

Funding

This work was supported by David K. Barker, ALP Life Sciences, Inc., Black Mountain, NC, United States for the publication fees.

Acknowledgments

We appreciate the guidance of Martin Root and Bob Swarthout from Appalachian State University, who served on the Master's committee for this project.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. McDonnell SL, French CB, Baggerly CA, Harris WS. Cross-sectional study of the combined associations of dietary and supplemental eicosapentaenoic acid+docosahexaenoic acid on omega-3 index. Nutr Res. (2019) 71:43–55. doi: 10.1016/j.nutres.2019.09.001

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Kris-Etherton PM, Grieger JA, Etherton TD. Dietary reference intakes for DHA and EPA. Prostaglandins Leukot Essent Fatty Acids. (2009) 81:99–104. doi: 10.1016/j.plefa.2009.05.011

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Medicine IO. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, Amino Acids. Washington, DC: The National Academies Press (2005).

PubMed Abstract | Google Scholar

4. Cholewski M, Tomczykowa M, Tomczyk M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. Nutrients. (2018) 10:1662. doi: 10.3390/nu10111662

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Papanikolaou Y, Brooks J, Reider C, Fulgoni VL III. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003–2008. Nutr J. (2014) 13:31. doi: 10.1186/1475-2891-13-31

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Fenton JI, Gurzell EA, Davidson EA, Harris WS. Red blood cell PUFAs reflect the phospholipid PUFA composition of major organs. Prostaglandins Leukot Essent Fatty Acids. (2016) 112:12–23. doi: 10.1016/j.plefa.2016.06.004

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. (2004) 39:212–20. doi: 10.1016/j.ypmed.2004.02.030

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res. (2014) 34:126–33. doi: 10.1016/j.nutres.2013.12.003

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Dretsch MN, Johnston D, Bradley RS, MacRae H, Deuster PA, Harris WS. Effects of omega-3 fatty acid supplementation on neurocognitive functioning and mood in deployed U.S. soldiers: a pilot study. Mil Med. (2014) 179:396–403. doi: 10.7205/MILMED-D-13-00395

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Lee JB, Notay K, Klingel SL, Chabowski A, Mutch DM, Millar PJ. Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women. Am J Physiol Heart Circ Physiol. (2019) 316:H873–81. doi: 10.1152/ajpheart.00677.2018

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Pieters DJ, Mensink RP. Effects of stearidonic acid on serum triacylglycerol concentrations in overweight and obese subjects: a randomized controlled trial. Eur J Clin Nutr. (2015) 69:121–6. doi: 10.1038/ejcn.2014.193

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients–a pilot study. Nephrol Dial Transplant. (2007) 22:3561–7. doi: 10.1093/ndt/gfm422

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Sarter B, Kelsey KS, Schwartz TA, Harris WS. Blood docosahexaenoic acid and eicosapentaenoic acid in vegans: associations with age and gender and effects of an algal-derived omega-3 fatty acid supplement. Clin Nutr. (2015) 34:212–8. doi: 10.1016/j.clnu.2014.03.003

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, et al. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. J Nutr Biochem. (2018) 58:28–36. doi: 10.1016/j.jnutbio.2018.03.025

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Stark KD, Van Elswyk ME, Higgins MR, Weatherford CA, Salem N Jr. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Prog Lipid Res. (2016) 63:132–52. doi: 10.1016/j.plipres.2016.05.001

PubMed Abstract | CrossRef Full Text | Google Scholar

16. van der Wurff ISM, von Schacky C, Bergeland T, Leontjevas R, Zeegers MP, Jolles J, et al. Effect of 1 year krill oil supplementation on cognitive achievement of dutch adolescents: a double-blind randomized controlled trial. Nutrients. (2019) 11: doi: 10.3390/nu11061230

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Grenon SM, Owens CD, Nosova EV, Hughes-Fulford M, Alley HF, Chong K, et al. High-dose fish oil supplementation increases the production of omega-3 fatty acid-derived mediators in patients with peripheral artery disease (the OMEGA-PAD I trial). J Am Heart Assoc. (2015) 4:e002034. doi: 10.1161/JAHA.115.002034

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Ramirez JL, Gasper WJ, Khetani SA, Zahner GJ, Hills NK, Mitchell PT, et al. Fish oil increases specialized pro-resolving lipid mediators in PAD (The OMEGA-PAD II trial). J Surg Res. (2019) 238:164–74. doi: 10.1016/j.jss.2019.01.038

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Zebrowska A, Hall B, Stolecka-Warzecha A, Stanula A, Sadowska-Krepa E. The effect of omega-3 fatty acid supplementation on serum adipocytokines, lipid profile and biochemical markers of inflammation in recreational runners. Nutrients. (2021) 13:456. doi: 10.3390/nu13020456

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Hooper C, De Souto Barreto P, Coley N, Cantet C, Cesari M, Andrieu S, et al. Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index. J Nutr Health Aging. (2017) 21:988–93. doi: 10.1007/s12603-017-0957-5

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Del Bo C, Deon V, Abello F, Massini G, Porrini M, Riso P, et al. Eight-week hempseed oil intervention improves the fatty acid composition of erythrocyte phospholipids and the omega-3 index, but does not affect the lipid profile in children and adolescents with primary hyperlipidemia. Food Res Int. (2019) 119:469–76. doi: 10.1016/j.foodres.2018.12.045

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Egert S, Lindenmeier M, Harnack K, Krome K, Erbersdobler HF, Wahrburg U, et al. Margarines fortified with alpha-linolenic acid, eicosapentaenoic acid, or docosahexaenoic acid alter the fatty acid composition of erythrocytes but do not affect the antioxidant status of healthy adults. J Nutr. (2012) 142:1638–44. doi: 10.3945/jn.112.161802

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Dams S, Holasek S, Tsiountsioura M, Edelsbrunner M, Dietz P, Koefeler H, et al. Effects of a plant-based fatty acid supplement and a powdered fruit, vegetable and berry juice concentrate on omega-3-indices and serum micronutrient concentrations in healthy subjects. Int J Food Sci Nutr. (2020) 71:769–80. doi: 10.1080/09637486.2020.1725960

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Witte AV, Kerti L, Hermannstadter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex. (2014) 24:3059–68. doi: 10.1093/cercor/bht163

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Massari M, Novielli C, Mando C, Di Francesco S, Della Porta M, Cazzola R, et al. Multiple micronutrients and docosahexaenoic acid supplementation during pregnancy: a randomized controlled study. Nutrients. (2020) 12:2432. doi: 10.3390/nu12082432

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Bukhari AS, Lutz LJ, Smith TJ, Hatch-McChesney A, O'Connor KL, Carrigan CT, et al. A food-based intervention in a military dining facility improves blood fatty acid profile. Nutrients. (2022) 14:743. doi: 10.3390/nu14040743

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Carboni S, Kaur G, Pryce A, McKee K, Desbois AP, Dick JR, et al. Mussel consumption as a “food first” approach to improve omega-3 status. Nutrients. (2019) 11:1381. doi: 10.3390/nu11061381

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Kohler A, Heinrich J, von Schacky C. Bioavailability of dietary omega-3 fatty acids added to a variety of sausages in healthy individuals. Nutrients. (2017) 9:629. doi: 10.3390/nu9060629

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Martucci M, Conte M, Bucci L, Giampieri E, Fabbri C, Palmas MG, et al. Twelve-week daily consumption of ad hoc fortified milk with omega-3, d, and group b vitamins has a positive impact on inflammaging parameters: a randomized cross-over trial. Nutrients. (2020) 12:3580. doi: 10.3390/nu12113580

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Stanton AV, James K, Brennan MM, O'Donovan F, Buskandar F, Shortall K, et al. Omega-3 index and blood pressure responses to eating foods naturally enriched with omega-3 polyunsaturated fatty acids: a randomized controlled trial. Sci Rep. (2020) 10:15444. doi: 10.1038/s41598-020-71801-5

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Handeland K, Skotheim S, Baste V, Graff IE, Froyland L, Lie O, et al. The effects of fatty fish intake on adolescents' nutritional status and associations with attention performance: results from the FINS-TEENS randomized controlled trial. Nutr J. (2018) 17:30. doi: 10.1186/s12937-018-0328-z

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Gerstenblith AT, Baskin DE, Shah CP, Wolfe JD, Fineman MS, Kaiser RS, et al. Electroretinographic effects of omega-3 Fatty Acid supplementation on dry age-related macular degeneration. JAMA Ophthalmol. (2013) 131:365–9. doi: 10.1001/jamaophthalmol.2013.642

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Tobin D, Brevik-Andersen M, Qin Y, Innes JK, Calder PC. Evaluation of a high concentrate omega-3 for correcting the omega-3 fatty acid nutritional deficiency in non-alcoholic fatty liver disease (CONDIN). Nutrients. (2018) 10:1126. doi: 10.20944/preprints201807.0240.v1

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, et al. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res. (2014) 55:1150–64. doi: 10.1194/jlr.M047357

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Sanguansri L, Augustin MA, Lockett TJ, Abeywardena MY, Royle PJ, Mano MT, et al. Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects. Br J Nutr. (2015) 113:822–31. doi: 10.1017/S000711451400436X

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Neubronner J, Schuchardt JP, Kressel G, Merkel M, von Schacky C, Hahn A. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur J Clin Nutr. (2011) 65:247–54. doi: 10.1038/ejcn.2010.239

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD, Hall S, Hill CL. Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. (2022) 116:672–85. doi: 10.1093/ajcn/nqac125

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Allaire J, Harris WS, Vors C, Charest A, Marin J, Jackson KH, et al. Supplementation with high-dose docosahexaenoic acid increases the omega-3 index more than high-dose eicosapentaenoic acid. Prostaglandins Leukot Essent Fatty Acids. (2017) 120:8–14. doi: 10.1016/j.plefa.2017.03.008

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Klingel SL, Metherel AH, Irfan M, Rajna A, Chabowski A, Bazinet RP, et al. EPA and DHA have divergent effects on serum triglycerides and lipogenesis, but similar effects on lipoprotein lipase activity: a randomized controlled trial. Am J Clin Nutr. (2019) 110:1502–9. doi: 10.1093/ajcn/nqz234

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Harris WS, Lemke SL, Hansen SN, Goldstein DA, DiRienzo MA, Su H, et al. Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. Lipids. (2008) 43:805–11. doi: 10.1007/s11745-008-3215-0

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Lemke SL, Maki KC, Hughes G, Taylor ML, Krul ES, Goldstein DA, et al. Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid. J Acad Nutr Diet. (2013) 113:1044–56. doi: 10.1016/j.jand.2013.04.020

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Lemke SL, Vicini JL, Su H, Goldstein DA, Nemeth MA, Krul ES, et al. Dietary intake of stearidonic acid-enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety. Am J Clin Nutr. (2010) 92:766–75. doi: 10.3945/ajcn.2009.29072

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Metherel AH, Irfan M, Klingel SL, Mutch DM, Bazinet RP. Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial. Am J Clin Nutr. (2019) 110:823–31. doi: 10.1093/ajcn/nqz097

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Mazahery H, Conlon CA, Beck KL, Mugridge O, Kruger MC, Stonehouse W, et al. A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder. J Steroid Biochem Mol Biol. (2019) 187:9–16. doi: 10.1016/j.jsbmb.2018.10.017

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Geppert J, Kraft V, Demmelmair H, Koletzko B. Docosahexaenoic acid supplementation in vegetarians effectively increases omega-3 index: a randomized trial. Lipids. (2005) 40:807–14. doi: 10.1007/s11745-005-1442-9

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Hedengran A, Szecsi PB, Dyerberg J, Harris WS, Stender S. n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial. Lipids. (2015) 50:165–75. doi: 10.1007/s11745-014-3968-6

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. (2004) 110:1645–9. doi: 10.1161/01.CIR.0000142292.10048.B2

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Lohner S, Fekete K, Marosvolgyi T, Decsi T. Gender differences in the long-chain polyunsaturated fatty acid status: systematic review of 51 publications. Ann Nutr Metab. (2013) 62:98–112. doi: 10.1159/000345599

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Harris WS, Pottala JV, Lacey SM, Vasan RS, Larson MG, Robins SJ. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis. (2012) 225:425–31. doi: 10.1016/j.atherosclerosis.2012.05.030

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Flock MR, Skulas-Ray AC, Harris WS, Etherton TD, Fleming JA, Kris-Etherton PM. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. J Am Heart Assoc. (2013) 2:e000513. doi: 10.1161/JAHA.113.000513

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Walker RE, Jackson KH, Tintle NL, Shearer GC, Bernasconi A, Masson S, et al. Predicting the effects of supplemental EPA and DHA on the omega-3 index. Am J Clin Nutr. (2019) 110:1034–40. doi: 10.1093/ajcn/nqz161

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. (2006) 83:1467–76S. doi: 10.1093/ajcn/83.6.1467S

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Alkhedhairi SA, Aba Alkhayl FF, Ismail AD, Rozendaal A, German M, MacLean B, et al. The effect of krill oil supplementation on skeletal muscle function and size in older adults: a randomised controlled trial. Clin Nutr. (2022) 41:1228–35. doi: 10.1016/j.clnu.2022.04.007

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Alqarni A, Mitchell TW, McGorry PD, Nelson B, Markulev C, Yuen HP, et al. Supplementation with the omega-3 long chain polyunsaturated fatty acids: changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. Schizophr Res. (2020) 226:52–60. doi: 10.1016/j.schres.2019.08.033

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Epitropoulos AT, Donnenfeld ED, Shah ZA, Holland EJ, Gross M, Faulkner WJ, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. (2016) 35:1185–91. doi: 10.1097/ICO.0000000000000940

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Heileson JL, Anzalone AJ, Carbuhn AF, Askow AT, Stone JD, Turner SM, et al. The effect of omega-3 fatty acids on a biomarker of head trauma in NCAA football athletes: a multi-site, non-randomized study. J Int Soc Sports Nutr. (2021) 18:65. doi: 10.1186/s12970-021-00461-1

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem. (2006) 52:2265–72. doi: 10.1373/clinchem.2006.072322

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Meital LT, Windsor MT, Ramirez Jewell RML, Young P, Schulze K, Magee R, et al. n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial. J Lipid Res. (2019) 60:1154–63. doi: 10.1194/jlr.P093013

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Macartney MJ, Hingley L, Brown MA, Peoples GE, McLennan PL. Intrinsic heart rate recovery after dynamic exercise is improved with an increased omega-3 index in healthy males. Br J Nutr. (2014) 112:1984–92. doi: 10.1017/S0007114514003146

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Hingley L, Macartney MJ, Brown MA, McLennan PL, Peoples GE. DHA-rich fish oil increases the omega-3 index and lowers the oxygen cost of physiologically stressful cycling in trained individuals. Int J Sport Nutr Exerc Metab. (2017) 27:335–43. doi: 10.1123/ijsnem.2016-0150

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Harris WS, Masson S, Barlera S, Milani V, Pileggi S, Franzosi MG, et al. Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial. Nutr Res. (2016) 36:989–94. doi: 10.1016/j.nutres.2016.06.012

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Yuen AW, Sander JW, Flugel D, Patsalos PN, Browning L, Bell GS, et al. Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations? Epilepsy Behav. (2008) 12:317–23. doi: 10.1016/j.yebeh.2007.10.015

PubMed Abstract | CrossRef Full Text | Google Scholar

63. West AL, Kindberg GM, Hustvedt SO, Calder PC. A novel self-micro-emulsifying delivery system enhances enrichment of eicosapentaenoic acid and docosahexaenoic acid after single and repeated dosing in healthy adults in a randomized trial. J Nutr. (2018) 148:1704–15. doi: 10.1093/jn/nxy127

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation. (2016) 134:378–91. doi: 10.1161/CIRCULATIONAHA.115.019949

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Wasserfurth P, Nebl J, Bosslau TK, Kruger K, Hahn A, Schuchardt JP. Intake of Calanus finmarchicus oil for 12 weeks improves omega-3 index in healthy older subjects engaging in an exercise programme. Br J Nutr. (2021) 125:432–9. doi: 10.1017/S0007114520002809

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Udani JK, Ritz BW. High potency fish oil supplement improves omega-3 fatty acid status in healthy adults: an open-label study using a web-based, virtual platform. Nutr J. (2013) 12:112. doi: 10.1186/1475-2891-12-112

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Kulzow N, Witte AV, Kerti L, Grittner U, Schuchardt JP, Hahn A, et al. Impact of omega-3 fatty acid supplementation on memory functions in healthy older adults. J Alzheimers Dis. (2016) 51:713–25. doi: 10.3233/JAD-150886

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Lee SM, Son YK, Kim SE, An WS. The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study. Mar Drugs. (2015) 13:741–55. doi: 10.3390/md13020741

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Rao A, Briskey D, Nalley JO, Ganuza E. Omega-3 eicosapentaenoic acid (EPA) rich extract from the microalga nannochloropsis decreases cholesterol in healthy individuals: a double-blind, randomized, placebo-controlled, three-month supplementation study. Nutrients. (2020) 12:1869. doi: 10.3390/nu12061869

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Combe N, Henry O, Lopez C, Vaysse C, Fonseca I, Ribaud D, et al. Hospital diet enriched with rapeseed or sunflower oils is associated with a decrease in plasma 16:1n-7 and some metabolic disorders in the elderly. Lipids. (2018) 53:145–55. doi: 10.1002/lipd.12012

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Ramprasath VR, Eyal I, Zchut S, Jones PJ. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. (2013) 12:178. doi: 10.1186/1476-511X-12-178

PubMed Abstract | CrossRef Full Text | Google Scholar